Rahul Dhanda is the co-founder, president, and CEO of Syntis Bio, a clinical-stage biopharmaceutical company revolutionizing oral therapy for obesity, diabetes, and rare diseases by unlocking the full therapeutic potential of the small intestine. He is also the co-founder and chairman of BLASTID, Inc., a spinout of Harvard Medical School funded through ARPA-H, and serves as an independent director at Constructive Bio. Prior to Syntis, Mr. Dhanda co-founded Sherlock Biosciences and led the company as president and CEO from inception to the launch of the first FDA-authorized CRISPR product. He also spent over a decade at T2 Biosystems in critical roles that guided the company to become a publicly traded, commercial leader in infectious disease diagnostics. Mr. Dhanda holds an MBA from MIT's Sloan School of Management and a BA from Wesleyan University. He is the author of Guiding Icarus: Merging Bioethics with Corporate Interests and an inventor on multiple patents with several scientific publications.